This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

DiaDexus, Inc. Appoints Dr. Oye Olukotun To Board Of Directors

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular products, today announced that its Board of Directors has appointed Adeoye (Oye) Y. Olukotun, M.D., M.P.H., F.A.C.C., F.A.H.A. as an independent director. Dr. Olukotun brings 35 years of medical experience to diaDexus, having worked in management positions across large pharmaceutical, biotechnology and major medical device companies. He currently serves as vice chairman of CardioVax, LLC and is an active board member for Nordion Inc.

“As a board certified cardiologist and experienced biotechnology and pharmaceutical company leader, Dr. Olukotun brings a unique mix of clinical, regulatory and commercial expertise in the cardiology space to diaDexus,” said Brian Ward, Ph.D., diaDexus' president and chief executive officer. “His experience will be critical as we prepare to seek FDA clearance of our Activity test in the U.S. and begin developing a robust pipeline of cardiovascular diagnostic products.”

Dr. Olukotun is a board certified cardiologist who has been instrumental in the submission of many New Drug Applications, Premarket Authorization Applications and 510(k) Applications. Prior to CardioVax, a company that seeks to advance technologies in the treatment of cardiovascular disease caused by atherosclerosis, Dr. Olukotun was a co-founder and chief medical officer at VIA Pharmaceuticals, a biotechnology company focused on the treatment of cardiovascular and metabolic diseases. Prior to that, he was the chief medical officer and senior vice president of clinical and regulatory affairs at Esperion Therapeutics, a cardiovascular drug development company, until its acquisition by Pfizer. From 1996 to 2000, Dr. Olukotun was vice president of medical and regulatory affairs and chief medical officer of Mallinckrodt, Inc., a global pharmaceutical company. Dr. Olukotun holds a B.A. degree in chemistry from the University of North Carolina, a M.D. degree from Albert Einstein College of Medicine and a M.P.H. degree from Harvard University School of Public Health. He trained in cardiovascular diseases and did his fellowship at Mayo Clinic in Rochester, Minnesota.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.20 +9.63 0.48%
NASDAQ 4,588.6910 +26.5020 0.58%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs